ArticleFrontiers in immunology2026
Molecular mechanism of propofol in reducing kidney injury induced by autologous orthotopic liver transplantation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study explores the mechanism of propofol in autologous orthotopic liver transplantation (AOLT)-insulted kidney injury. Methods: A rat model of OALT-induced kidney injury was established, followed by intraperitoneal injection of propofol. Rat renal tubular epithelial cells (RTECs) were induced by hypoxia/reoxygenation. Renal pathological changes were observed via H&E and PAS staining. TNF-α, IL-8, IL-6, IL-1β, and IL-18 levels were measured via ELISA. NLRP3, cleaved Caspase-1, and GSDMD-N expressions were tested via Western blot. The binding of SIRT1 to FOXO3a, SIRT1 to ASC, and ASC to NLRP3, as well as acetylation levels of FOXO3a, ASC, and NLRP3 were analyzed via immunoprecipitation. The binding between FOXO3a and ASC was verified via Ch-IP and dual luciferase assays. Results: SIRT1 expression is augmented in rat kidney tissues following AOLT, and propofol further elevates SIRT1 expression. Propofol alleviates AOLT-induced kidney injury and pyroptosis. Mechanistically, SIRT1 binds to FOXO3a in the nucleus to inhibit its acetylation, thereby reducing ASC expression. Moreover, SIRT1 binds to ASC in the cytoplasm to inhibit its acetylation, thereby inhibiting the binding of ASC to NLRP3. Conclusion: In conclusion, Propofol promotes SIRT1-mediated deacetylation to inhibit RTEC pyroptosis via FOXO3a/ASC/NLRP3 axis and alleviate AOLT-induced kidney injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.